Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Accounts Payables (2020 - 2025)

Cytek Biosciences' Accounts Payables history spans 6 years, with the latest figure at $6.4 million for Q4 2025.

  • For Q4 2025, Accounts Payables rose 15.93% year-over-year to $6.4 million; the TTM value through Dec 2025 reached $6.4 million, up 15.93%, while the annual FY2025 figure was $6.4 million, 15.93% up from the prior year.
  • Accounts Payables reached $6.4 million in Q4 2025 per CTKB's latest filing, down from $7.6 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $7.6 million in Q3 2025 to a low of $3.0 million in Q4 2023.
  • Average Accounts Payables over 5 years is $5.0 million, with a median of $5.3 million recorded in 2023.
  • Peak YoY movement for Accounts Payables: tumbled 54.33% in 2023, then skyrocketed 114.76% in 2025.
  • A 5-year view of Accounts Payables shows it stood at $3.0 million in 2021, then soared by 58.37% to $4.8 million in 2022, then crashed by 36.9% to $3.0 million in 2023, then skyrocketed by 82.35% to $5.5 million in 2024, then rose by 15.93% to $6.4 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Accounts Payables are $6.4 million (Q4 2025), $7.6 million (Q3 2025), and $6.9 million (Q2 2025).